BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 25, 2011
 |  BC Week In Review  |  Company News  |  Deals

KAHR, sanofi-aventis deal

In connection with its $2 million investment, sanofi-aventis received an option to the first right of negotiation to one of KAHR's two preclinical compounds. KAHR-101 is a fusion protein...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >